Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy

Sun, 06/09/2019 - 7:20pm

Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of...

      Related Stories 

Amyloidosis Drug Competitors Can Coexist While Growing The Market, Alnylam CEO Says

Fri, 06/07/2019 - 3:51pm

The recent US FDA approval of three drugs – Alnylam’s Onpattro, Ionis’ Tegsedi and Pfizer’s tafamidis – in transthyretin-mediated amyloidosis...

      Related Stories 

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

Fri, 06/07/2019 - 1:42pm

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing...

      Related Stories 

The Challenges Facing Paul Hudson At the Helm of Sanofi

Fri, 06/07/2019 - 8:20am

Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and...

      Related Stories 

Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

Fri, 06/07/2019 - 6:57am

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease...

      Related Stories 

BeiGene, Hengrui Among China Firms Flexing New Oncology Muscle At ASCO

Thu, 06/06/2019 - 8:25pm

In its bid to facilitate novel treatments for some of its most prevalent cancers, China is also poised to make...

      Related Stories 

Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline

Thu, 06/06/2019 - 6:10pm

Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.

      Related Stories 

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

Thu, 06/06/2019 - 1:57pm

News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former...

      Related Stories 

AZ’s Calquence Hits Endpoint In Second CLL Phase III Study

Thu, 06/06/2019 - 7:29am

The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.

      Related Stories 

Aceto Claims Aurobindo Caused Its Collapse

Thu, 06/06/2019 - 7:24am

Aceto has blamed Aurobindo for its downfall, alleging a series of calculated and deceitful actions that have critically wounded the...

      Related Stories 

With New Leadership, Roche Goes Back To Basics At ASCO

Wed, 06/05/2019 - 6:59pm

In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the...

      Related Stories 

BIO 2019 Notebook: Merck On Finding The Right Balance, Sandoz On The Next Wave Of Biosimilars, NORD On Patient Engagement

Wed, 06/05/2019 - 4:32pm

News and views from day three of the BIO International Convention: Merck’s Frazier champions both social justice and capitalism; ...

      Related Stories 

Bristol Unveils Post-Celgene Leadership Team, With Big R&D Changes

Wed, 06/05/2019 - 12:45pm

Novartis's Hirawat will join the company as chief medical officer, while Celgene's Vessey will head early research. Bristol's current chief...

      Related Stories 

Pages